These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 39367371)
1. Real world evidence on the effectiveness and safety of tofacitinib in ulcerative colitis in Lebanon. Sharara AI; Alrazim A; Saniour P; Daniel F; Rached AA; Bahr A; Azar C; Geagea A; Ghoubar M BMC Gastroenterol; 2024 Oct; 24(1):349. PubMed ID: 39367371 [TBL] [Abstract][Full Text] [Related]
2. Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort. Dalal RS; Sharma PP; Bains K; Pruce JC; Allegretti JR Inflamm Bowel Dis; 2024 Oct; 30(10):1707-1713. PubMed ID: 37843044 [TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study. Yoon H; Ye BD; Kang SB; Lee KM; Choi CH; Jo JY; Woo J; Cheon JH BMC Gastroenterol; 2024 Aug; 24(1):273. PubMed ID: 39160459 [TBL] [Abstract][Full Text] [Related]
4. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480 [TBL] [Abstract][Full Text] [Related]
5. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience. Parra-Izquierdo V; Frías-Ordoñez JS; Cuadros C; Vargas M; Vera Chamorro JF; Romero Sanchez C; Flórez-Sarmiento C Gastroenterol Hepatol; 2024; 47(6):574-581. PubMed ID: 37820832 [TBL] [Abstract][Full Text] [Related]
6. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study. Carvalhas Gabrielli AM; Ferretti F; Monico CM; Tombetti E; Maconi G; Romeo S; Piazza O Sed N; Caprioli F; Mazzola AM; Alicante S; Bertè R; Lolli E; Scribano ML; Buscarini E; Ricci C; Carmagnola S; Ardizzone S; Cannatelli R Dig Dis Sci; 2024 May; 69(5):1785-1792. PubMed ID: 38530500 [TBL] [Abstract][Full Text] [Related]
7. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ; Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087 [TBL] [Abstract][Full Text] [Related]
8. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience. Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA; J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965 [TBL] [Abstract][Full Text] [Related]
9. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444 [TBL] [Abstract][Full Text] [Related]
10. Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis. Lopes SR; Martins C; Teixeira M; Tomás D World J Gastroenterol; 2024 Sep; 30(34):3929-3931. PubMed ID: 39350781 [TBL] [Abstract][Full Text] [Related]
11. Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: A case series study. Parra-Izquierdo V; Frías-Ordoñez JS; Juliao-Baños F; Cuadros C; Romero Sanchez C; Flórez-Sarmiento C Gastroenterol Hepatol; 2024; 47(6):582-590. PubMed ID: 37806342 [TBL] [Abstract][Full Text] [Related]
12. Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study. Ollech JE; Eran-Banai H; Goren I; Sharar Fischler T; Avni-Biron I; Snir Y; Broitman Y; Cohen S; Friedenberg A; Pauker MH; Dotan I; Yanai H Ann Med; 2024 Dec; 56(1):2358183. PubMed ID: 38813808 [TBL] [Abstract][Full Text] [Related]
13. Upfront tofacitinib in patients with biological-naïve ulcerative colitis - An Indian multicentric experience. Giri S; Bhrugumalla S; Kamuni A; Mishra D; Pati GK; Agrawal D; Verma G; Wagh R; Chauhan S; Ingle M; Chandnani S; Jain S; Rathi PM; Shukla A; Kale A Indian J Gastroenterol; 2024 Feb; 43(1):237-243. PubMed ID: 37726491 [TBL] [Abstract][Full Text] [Related]
14. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study. Shin SH; Oh K; Hong SN; Lee J; Oh SJ; Kim ES; Na SY; Kang SB; Koh SJ; Bang KB; Jung SA; Jung SH; Kim KO; Park SH; Yang SK; Choi CH; Ye BD Therap Adv Gastroenterol; 2023; 16():17562848231154103. PubMed ID: 36950251 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. Pantavou K; Yiallourou AI; Piovani D; Evripidou D; Danese S; Peyrin-Biroulet L; Bonovas S; Nikolopoulos GK United European Gastroenterol J; 2019 Dec; 7(10):1285-1303. PubMed ID: 31839954 [TBL] [Abstract][Full Text] [Related]
17. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel. Avni-Biron I; Bar-Gil Shitrit A; Koslowsky B; Levartovsky A; Kopylov U; Weisshof R; Aviv Cohen N; Maharshak N; Hovel D; Israeli E; Naftali T; Goren I; Snir Y; Ollech JE; Banai-Eran H; Broitman Y; Sharar-Fischler T; Dotan I; Yanai H Dig Liver Dis; 2022 Feb; 54(2):192-197. PubMed ID: 34887214 [TBL] [Abstract][Full Text] [Related]
18. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience. Parra-Izquierdo V; Frías-Ordoñez JS; Márquez JR; Juliao-Baños F; Galindo P; Cuadros C; Rojas C; Rojas N; Ardila O; Tovar-Fierro G; García-Duperly R; Vargas M; Flórez-Sarmiento C Gastroenterol Hepatol; 2023; 46(7):512-521. PubMed ID: 36372256 [TBL] [Abstract][Full Text] [Related]
19. Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. Resál T; Bacsur P; Keresztes C; Bálint A; Bor R; Fábián A; Farkas B; Katsanos K; Michalopoylos G; Ribaldone DG; Attauabi M; Zhao M; Barak HA; Yanai H; Bezzio C; Rispo A; Castiglione F; Bar-Gil Shitrit A; Pugliese D; Armuzzi A; Savarino EV; Kolar M; Lukáš M; Chashkova E; Filip R; Rozieres A; Nancey S; Krznarić Ž; Schäfer E; Szamosi T; Sarlós P; Franko M; Drobne D; Knyazev OV; Kagramanova AV; Limdi J; Wetwittayakhlang P; Lakatos PL; Maharshak N; Bannon L; Nyári T; Szepes Z; Farkas K; ; Molnár T Inflamm Bowel Dis; 2024 May; 30(5):768-779. PubMed ID: 37542737 [TBL] [Abstract][Full Text] [Related]
20. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis. Kojima K; Watanabe K; Kawai M; Yagi S; Kaku K; Ikenouchi M; Sato T; Kamikozuru K; Yokoyama Y; Takagawa T; Shimizu M; Shinzaki S World J Gastroenterol; 2024 Apr; 30(13):1871-1886. PubMed ID: 38659488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]